Clinical Trials Logo

Filter by:
NCT ID: NCT00034463 Completed - Cancer Clinical Trials

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Start date: n/a
Phase: Phase 1
Study type: Interventional

This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.

NCT ID: NCT00034489 Completed - Breast Neoplasms Clinical Trials

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Start date: n/a
Phase: Phase 2
Study type: Interventional

This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.

NCT ID: NCT00034502 Completed - Colorectal Cancer Clinical Trials

A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.

NCT ID: NCT00034567 Completed - Alzheimer Disease Clinical Trials

Healthy Aging and Memory Study

Start date: n/a
Phase: N/A
Study type: Observational

This project will focus on the development and testing of efficient, cost effective measures that are specifically designed for use in Alzheimer's Disease (AD) primary prevention trials.

NCT ID: NCT00034593 Completed - Urologic Neoplasms Clinical Trials

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Start date: n/a
Phase: Phase 2
Study type: Interventional

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

NCT ID: NCT00034606 Completed - Neoplasms Clinical Trials

Comparing 3 Schedules of Alimta Plus Gemzar

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

NCT ID: NCT00034619 Completed - Colorectal Cancer Clinical Trials

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

NCT ID: NCT00034957 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Start date: n/a
Phase: Phase 2
Study type: Interventional

The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)

NCT ID: NCT00035035 Completed - Clinical trials for Pancreatic Neoplasms

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Start date: n/a
Phase: Phase 3
Study type: Interventional

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

NCT ID: NCT00035061 Completed - Urologic Neoplasms Clinical Trials

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Start date: n/a
Phase: Phase 2
Study type: Interventional

Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.